Coherus Oncology, Inc.
Clinical trials sponsored by Coherus Oncology, Inc., explained in plain language.
Biopharmaceutical company focused on oncology immunotherapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug CHS-114 enters first human tests Results expected Sep 2026 (estimated)
- New cocktail aims to shrink untreatable liver tumors Results expected Sep 2027 (estimated)
-
New cancer drug CHS-114 enters first human tests
Disease control OngoingThis early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…
Phase 1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cocktail aims to shrink untreatable liver tumors
Disease control OngoingThis Phase 2 trial tests whether adding the experimental drug casdozokitug to a standard immunotherapy combination (toripalimab plus bevacizumab) can safely shrink tumors in people with advanced liver cancer that cannot be removed by surgery. The study enrolls 72 participants and…
Phase 2 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC